With a market cap of $681.8 billion, Eli Lilly and Company (LLY) is a leading global pharmaceutical company focused on ...

We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at ...

Eli Lilly and Company (NYSE:LLY) is expanding its footprint into the non-opioid pain management market in pursuit of growth ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

Transaction will augment Lilly's efforts to advance non-opioid medicines for pain management INDIANAPOLIS, May 27, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...

The U.S. imports more pharmaceutical products from Ireland than from any other country -- nearly $50 billion last year. It won't be surprising if the Trump administration especially targets those ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...